Immunovant’s plans for autoimmune asset; Wall Street worries about Moderna’s RSV candidate 

Plus, news about Novo Holdings, Gritstone Bio, Invivyd and Science 37:

Immunovant outlines big plans for its autoimmune program: The biotech now expects to launch four to five “potentially registrational” trials for IMVT-1402 by March 2025 and studies in up to 10 indications by March 2026….
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks